The FDA has approved a new daily pill for certain patients with metastatic pancreatic cancer. In a 500-patient trial, median survival increased from around 6.7 months to more than 13 months, offering new hope against one of the hardest cancers to treat. Researchers hope the approach could eventually have applications in other hard-to-treat cancers.
Subscribe: http://trt.world/subscribe
Livestream: http://trt.world/ytlive
Facebook: http://trt.world/facebook
X (Twitter): http://trt.world/twitter
Instagram: http://trt.world/instagram
TikTok: http://tiktok.com/@trtworld
WhatsApp: trtworld.com/whatsapp
Telegram: https://t.me/trtworld
Visit our website: http://trt.world
